Rheumatoid Factor Solution Catalog number: S2010001 Lot number: Batch dependent Expiration date: Batch depdendent Concentration: ≥1500 IU/mL Package Size: 1 mL Appearance: Slightly turbid Species: Human Matrix: Defibrinated human plasma Storage: -20°C. Avoid repeated freeze-thaw. Other names: RF, rheumatoid arthritis factor, rheumatoid arthritis antibody Keywords: Rheumatoid Factor, RF, rheumatoid arthritis factor, rheumatoid arthritis antibody Rheumatoid Factor Solution is a high-titer human plasma-based reagent containing ≥1500 IU/mL of rheumatoid factor (RF), a key autoantibody associated with rheumatoid arthritis and other autoimmune conditions. This solution is formulated from defibrinated human plasma and exhibits a slightly turbid appearance, reflecting its native immunoglobulin content. It is ideal for interference testing, assay validation, and immunoassay robustness studies where RF cross-reactivity or signal distortion must be evaluated. Researchers use this solution to simulate RF-positive specimens in diagnostic workflows, assess assay specificity, and validate blocking strategies. Its high concentration and native matrix make it suitable for ELISA, nephelometry, and other immunometric platforms. All components are biotechnology grade and filtered through 0.22 μm membranes using Type I ultrapure water (resistivity >18 MΩ·cm). Key Features: High-titer RF concentration (≥1500 IU/mL) for interference modeling Human plasma matrix ensures physiological relevance Validated for immunoassay robustness and specificity testing Biotechnology grade with 0.22 μm filtration for purity and consistency RUO designation: not for clinical or therapeutic applications Indication for Use:This product is for Research Use Only. It is not intended for human or animal use, diagnostic procedures, or therapeutic applications. All Interference Products Brochure References: Hollander, J. L. (1968). Rheumatoid Arthritis, Rheumatoid Factor, and Gamma G Globulin Fragments. Annals of Internal Medicine, 68(5), 1195. Pappas, D. A., and Bathon, J. M. (2009). Treatment of Rheumatoid Arthritis: Tumor Necrosis Factor Inhibitors. Rheumatoid Arthritis, 337–349. Shingu, M., Ezaki, I., and Nobunaga, M. (1988). Complement-activating properties of immune complexes are suppressed by IgM rheumatoid factor and enhanced by IgG rheumatoid factor. Rheumatology International, 8(3), 95–100. Vaughan, J. H. (1993). Pathogenetic concepts and origins of rheumatoid factor in rheumatoid arthritis. Arthritis and Rheumatism, 36(1), 1–6. Xing Q, Fu L, Yu Z, Zhou X. Efficacy and Safety of Integrated Traditional Chinese Medicine and Western Medicine on the Treatment of Rheumatoid Arthritis: A Meta-Analysis. Evid Based Complement Alternat Med. 2020 Apr 2;2020:4348709. PubMed Raine C, Austin K, Giles I. Mechanisms determining the amelioration of rheumatoid arthritis in pregnancy: A systematic review. Semin Arthritis Rheum. 2020 Mar 19. pii: S0049-0172(20)30079-2. Toussirot E. The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition. Metabolites. 2020 Mar 13;10(3). pii: E107. PubMed Ishikawa Y, Terao C. The Impact of Cigarette Smoking on Risk of Rheumatoid Arthritis: A Narrative Review. Cells. 2020 Feb 19;9(2). pii: E475. Lin YJ, Anzaghe M, Schülke S. Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells. 2020 Apr 3;9(4). pii: E880. Capone A, Volpe E. Transcriptional Regulators of T Helper 17 Cell Differentiation in Health and Autoimmune Diseases. Front Immunol. 2020 Mar 12;11:348.
